サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1552746

髄膜炎治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

Meningitis Treatment Market (Causative Organism: Bacterial, Viral, and Fungal; and Type of Treatment: Antibiotic Therapy and Adjunctive Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 158 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.06円
髄膜炎治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年
出版日: 2024年07月04日
発行: Transparency Market Research
ページ情報: 英文 158 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

髄膜炎治療市場- 調査範囲

TMRの調査レポート「髄膜炎治療の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の髄膜炎治療市場の収益と予測を提供しています。また、2024年から2034年までの世界の髄膜炎治療市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、髄膜炎治療市場を推察しました。

市場スナップショット
2023年の市場規模 1億5,090万米ドル
2034年の市場規模 2億3,480万米ドル
CAGR 4.1%

当レポートでは、世界の髄膜炎治療市場の競合情勢について調査しています。世界の髄膜炎治療市場で事業を展開する主要企業が特定され、各企業がさまざまな属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の髄膜炎治療市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：原因生物別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：原因生物別、2020-2034年
    • 細菌性
    • ウイルス性
    • 真菌性
  • 市場の魅力：原因生物別

第7章 世界の市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療タイプ別、2020-2034年
    • 抗生物質療法
    • 補助療法
  • 市場の魅力：治療タイプ別

第8章 世界の市場分析と予測：ワクチンの種類別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：ワクチンの種類別、2020-2034年
    • 髄膜炎菌結合ワクチン
    • 髄膜炎菌多糖体ワクチン（MPSV4）
    • 混合ワクチン
  • 市場の魅力：ワクチンの種類別

第9章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：流通チャネル別、2020-2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力：流通チャネル別

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋地域の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023）
  • 企業プロファイル
    • Bio-med（P）Ltd.
    • Novartis AG
    • Nuron Biotech, Inc.
    • Pfizer Inc.
    • Baxter International Inc.
    • Merck & Co. Inc.
    • Sanofi S.A.
    • GSK PLC
    • F. Hoffmann-Roche AG
    • Athlone Laboratories Limited
    • Wockhardt
図表

List of Tables

  • Table 01: Global Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 02: Global Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 03: Global Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 05: Global Meningitis Treatment Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Meningitis Treatment Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 08: North America Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 09: North America Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 10: North America Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe Meningitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 13: Europe Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 14: Europe Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 15: Europe Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific Meningitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 18: Asia Pacific Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 19: Asia Pacific Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 20: Asia Pacific Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America Meningitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 23: Latin America Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 24: Latin America Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 25: Latin America Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast, by Causative Organism, 2020-2034
  • Table 28: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2020-2034
  • Table 29: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast, by Vaccine Type, 2020-2034
  • Table 30: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Meningitis Treatment Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Meningitis Treatment Market Revenue (US$ Mn), by Causative Organism, 2023
  • Figure 03: Global Meningitis Treatment Market Value Share, by Causative Organism, 2023
  • Figure 04: Global Meningitis Treatment Market Revenue (US$ Mn), by Treatment Type, 2023
  • Figure 05: Global Meningitis Treatment Market Value Share, by Treatment Type, 2023
  • Figure 06: Global Meningitis Treatment Market Revenue (US$ Mn), by Vaccine Type, 2023
  • Figure 07: Global Meningitis Treatment Market Value Share, by Vaccine Type, 2023
  • Figure 08: Global Meningitis Treatment Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 09: Global Meningitis Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global Meningitis Treatment Market Value Share, by Region, 2023
  • Figure 11: Global Meningitis Treatment Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 13: Global Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 14: Global Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 15: Global Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 16: Global Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 17: Global Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 18: Global Meningitis Treatment Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 19: Global Meningitis Treatment Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global Meningitis Treatment Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Meningitis Treatment Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Meningitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Meningitis Treatment Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Meningitis Treatment Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 26: North America Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 27: North America Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 28: North America Meningitis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 30: North America Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 31: North America Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 32: North America Meningitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe Meningitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Meningitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Meningitis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 37: Europe Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 38: Europe Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 39: Europe Meningitis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 41: Europe Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 42: Europe Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 43: Europe Meningitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific Meningitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Meningitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Meningitis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 48: Asia Pacific Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 49: Asia Pacific Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 50: Asia Pacific Meningitis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 52: Asia Pacific Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 53: Asia Pacific Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 54: Asia Pacific Meningitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America Meningitis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Meningitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Meningitis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 59: Latin America Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 60: Latin America Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 61: Latin America Meningitis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 63: Latin America Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 64: Latin America Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 65: Latin America Meningitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa Meningitis Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Meningitis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Meningitis Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Meningitis Treatment Market Value Share Analysis, by Causative Organism, 2023 and 2034
  • Figure 70: Middle East & Africa Meningitis Treatment Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 71: Middle East & Africa Meningitis Treatment Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 72: Middle East & Africa Meningitis Treatment Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa Meningitis Treatment Market Attractiveness Analysis, by Causative Organism, 2024-2034
  • Figure 74: Middle East & Africa Meningitis Treatment Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 75: Middle East & Africa Meningitis Treatment Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 76: Middle East & Africa Meningitis Treatment Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL86291

Meningitis Treatment Market - Scope of Report

TMR's report on the global meningitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global meningitis treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningitis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningitis treatment market.

Market Snapshot
Market Value in 2023US$ 150.9 Mn
Market Value in 2034US$ 234.8 Mn
CAGR4.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global meningitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global meningitis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global meningitis treatment market.

The report delves into the competitive landscape of the global meningitis treatment market. Key players operating in the global meningitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global meningitis treatment market profiled in this report.

Key Questions Answered in Global meningitis treatment Market Report:

  • What is the sales/revenue generated by meningitis treatment across all regions during the forecast period?
  • What are the opportunities in the global meningitis treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Meningitis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global meningitis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global meningitis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global meningitis treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Meningitis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Meningitis Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Meningitis Treatment Market Analysis and Forecast, by Causative Organism

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Causative Organism, 2020-2034
    • 6.3.1. Bacterial
    • 6.3.2. Viral
    • 6.3.3. Fungal
  • 6.4. Market Attractiveness, by Causative Organism

7. Global Meningitis Treatment Market Analysis and Forecast, by Treatment Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 7.3.1. Antibiotic Therapy
    • 7.3.2. Adjunctive Therapy
  • 7.4. Market Attractiveness, by Treatment Type

8. Global Meningitis Treatment Market Analysis and Forecast, by Vaccine Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Vaccine Type, 2020-2034
    • 8.3.1. Meningococcal Conjugate Vaccine
    • 8.3.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 8.3.3. Combination Vaccines
  • 8.4. Market Attractiveness, by Vaccine Type

9. Global Meningitis Treatment Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Meningitis Treatment Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Meningitis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 11.2.1. Bacterial
    • 11.2.2. Viral
    • 11.2.3. Fungal
  • 11.3. Market Attractiveness, by Causative Organism
  • 11.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.4.1. Antibiotic Therapy
    • 11.4.2. Adjunctive Therapy
  • 11.5. Market Attractiveness, by Treatment Type
  • 11.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 11.6.1. Meningococcal Conjugate Vaccine
    • 11.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 11.6.3. Combination Vaccines
  • 11.7. Market Attractiveness, by Vaccine Type
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. Online Pharmacy
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Causative Organism
    • 11.11.2. By Treatment Type
    • 11.11.3. By Vaccine Type
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Meningitis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 12.2.1. Bacterial
    • 12.2.2. Viral
    • 12.2.3. Fungal
  • 12.3. Market Attractiveness, by Causative Organism
  • 12.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.4.1. Antibiotic Therapy
    • 12.4.2. Adjunctive Therapy
  • 12.5. Market Attractiveness, by Treatment Type
  • 12.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 12.6.1. Meningococcal Conjugate Vaccine
    • 12.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 12.6.3. Combination Vaccines
  • 12.7. Market Attractiveness, by Vaccine Type
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Online Pharmacy
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Causative Organism
    • 12.11.2. By Treatment Type
    • 12.11.3. By Vaccine Type
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Meningitis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 13.2.1. Bacterial
    • 13.2.2. Viral
    • 13.2.3. Fungal
  • 13.3. Market Attractiveness, by Causative Organism
  • 13.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.4.1. Antibiotic Therapy
    • 13.4.2. Adjunctive Therapy
  • 13.5. Market Attractiveness, by Treatment Type
  • 13.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 13.6.1. Meningococcal Conjugate Vaccine
    • 13.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 13.6.3. Combination Vaccines
  • 13.7. Market Attractiveness, by Vaccine Type
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. Online Pharmacy
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Causative Organism
    • 13.11.2. By Treatment Type
    • 13.11.3. By Vaccine Type
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Meningitis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 14.2.1. Bacterial
    • 14.2.2. Viral
    • 14.2.3. Fungal
  • 14.3. Market Attractiveness, by Causative Organism
  • 14.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.4.1. Antibiotic Therapy
    • 14.4.2. Adjunctive Therapy
  • 14.5. Market Attractiveness, by Treatment Type
  • 14.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 14.6.1. Meningococcal Conjugate Vaccine
    • 14.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 14.6.3. Combination Vaccines
  • 14.7. Market Attractiveness, by Vaccine Type
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. Online Pharmacy
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Causative Organism
    • 14.11.2. By Treatment Type
    • 14.11.3. By Vaccine Type
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Meningitis Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 15.2.1. Bacterial
    • 15.2.2. Viral
    • 15.2.3. Fungal
  • 15.3. Market Attractiveness, by Causative Organism
  • 15.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 15.4.1. Antibiotic Therapy
    • 15.4.2. Adjunctive Therapy
  • 15.5. Market Attractiveness, by Treatment Type
  • 15.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 15.6.1. Meningococcal Conjugate Vaccine
    • 15.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 15.6.3. Combination Vaccines
  • 15.7. Market Attractiveness, by Vaccine Type
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. Online Pharmacy
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Causative Organism
    • 15.11.2. By Treatment Type
    • 15.11.3. By Vaccine Type
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Bio-med (P) Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Nuron Biotech, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Pfizer Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Baxter International Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co. Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Sanofi S.A.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. GSK PLC
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. F. Hoffmann-Roche AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Athlone Laboratories Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Wockhardt
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview